MALIGNANT MELANOMA
Prof. Camillo O. DI CICCO, M.D.
==============================================================
Melanoma is the most aggressive of malignant cutaneous tumours. Because cases presenting with lymphonode involvement and distant metastases carry a very poor prognosis (50% and 20% respectively alive in 5 years) while on the contrary those presenting without evident lymphonode involvement have a much better survival (60% alive in 5 years).
Survival is moreover directly related to the depth of tumour invasion:
Melanoma thickness - 10 yr survival
< 1.0 mm. - 90%
1.0 / 1.49 mm. - 78%
1.50 / 4.00 mm. - 65%
> 4.00 mm. - 40%
It is therefore extremely important a malignant melanoma early diagnosis according to the ABCD rules listed on page 3.
The purpose of this site is to make know (health care professionals and visitors) the most important works reported worldwide on malignant melanoma.

MELANOMA DERMATLAS JOHNS HOPKINS UNIVERSITY
MELANOMA AND CUTANEOUS ONCOLOGY GROUP ( The Johns Hopkins Oncology Center )
CLINICAL TRIALS

Clinical Trials: Malignant Melanoma.
Metastatic Melanoma Study - Autologous Vaccine Study in patients with Stage III melanoma -Study of bone transplantation procedure in patients who have metastatic malignant melanoma, this treatment involves high dose chemotherapy followed by donor bone marrow to elicit an immune anticancer effect from the donor cells.

CANCER LINKS - MELANOMA
UNIVERSITY OF WASHINGTON - MELANOMA
SITES OF INTEREST TO DERMATOLOGISTS
AMERICAN ACADEMY OF DERMATOLOGY
DERMATOLOGY EVENTS WORLDWIDE
NEXT